Overview

Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of single doses of QAB149 up to 3000 µg delivered via a single-dose, dry powder inhaler in patients with mild to moderate COPD.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis